BBIO logo

BBIO BridgeBio Pharma, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$78.07
+1.27 (+1.66%)

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 …

Market Cap: $15.21Bwww.bridgebio.com

Price

$79.86+67.46%
$44.81$59.93$75.05$90.17
Jul 2025Aug 2026

Social Signal Score

51
5d
—
30d
51
12 mentions
+0.0%
60d
50
23 mentions
+0.0%
90d
52
42 mentions
+0.0%
news: 32 · marketaux: 3 · rss: 7

Analyst Ratings

28 analysts
Buyconsensus
Strong Buy 0Buy 25Hold 3Sell 0Strong Sell 0
Avg price target$110.18+41.1%
Low $87Median $107High $156
Current Consensus

52-week range

$47.29$90.17
Last close
$79.86
Off 52w high
-11.4%
200-day average
$72.71
vs 200-day
+9.8%

Revenue

$353.17M
$0.00$117.72M$235.45M$353.17M
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-3.44
$-3.56–$-3.28
7 analysts
FY2026
$-2.68
$-3.09–$-1.97
11 analysts
FY2027
$-0.81
$-1.88–$1.10
12 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Neil Kumar
Sector
Healthcare
Industry
Biotechnology
Employees
1,001
Beta
0.97
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-0.01
www.bridgebio.com